Two more pet-related spinoffs on tap

ELI LILLY & CO. $105 (New York symbol LLY; Manufacturing & Industry sector; Shares outstanding: 1.1 billion; Market cap: $115.5 billion; Dividend yield: 2.1%; Takeover Target Rating: Low; www.lilly.com) develops, makes and markets drugs and animal-health products.
Lilly hopes to match the success Pfizer realized with its Zoetis spinoff… Read More

Second spinoff set to unlock value

Pfizer’s shares have gained 50% in the five years since it used an initial public offering to set up its animal-drug business as Zoetis. It then offered its remaining shares to investors. The new company now plans to sell or spin off its consumer business,… Read More

Rising food demand spurs these two funds

With yearly revenue of $4 trillion, the global agriculture industry offers enormous opportunities for firms ready to satisfy growing food demand. (For more on agriculture, see supplement, page 10.)

VANECK VECTORS AGRICULTURE AGRIBUSINESS ETF $59 (New York symbol MOO; TSINetwork ETF Rating: Aggressive; Market cap: $831.4… Read More

Strong Sustainability for Pfizer dividend

For our December issue of TSI Dividend Advisor we reported on Pfizer’s research spending and recent acquisitions. They will contribute significantly to its future growth.

PFIZER INC. $31 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares o/s: 6.1 billion; Market cap: $189.1 billion;… Read More

Research and acquisitions pay off for Pfizer

PFIZER INC. $31 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares o/s: 6.1 billion; Market cap: $189.1 billion; Price-to-sales ratio: 3.6; Dividend Sustainability Rating: Highest; Dividend yield: 3.9%; www.pfizer.com) is one of the world’s leading prescription drugmakers. Its top-selling brands include Lyrica… Read More

PFIZER INC. $32 – New York symbol PFE

PFIZER INC. $32 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 6.5 billion; Market cap: $208.0 billion; Price-to-sales ratio: 4.0; Dividend yield: 3.3%; TSINetwork Rating: Above Average; www.pfizer.com) is the world’s largest pharmaceutical company.

Pfizer gets about 45% of its revenue from… Read More

Why Pfizer is special

Drug stocks operate under distinct negatives. For example, new drugs take years to win regulatory approval, if ever. As well, they face increasing litigation and aggressive competition from generics.

However, we feel Pfizer will continue to overcome these challenges. Its high research spending is letting… Read More